ArticleMovement disorders clinical practice2025
Longitudinal Assessment Reveals Stage-Dependent Utility of Digital Motor Markers in SCA1.
Article in Movement disorders clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Feasibility of a smartphone application for remote use in spastic ataxias: an 8-week long-term PROSPAX study.Journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundClinical trials in spinocerebellar ataxias (SCA) require objective, quantifiable outcome measures sensitive to changes in disease severity.
objectivesThe objective was to study the sensitivity to change of digital gait biomarkers in SCA1 over a 1-year period.
methodsSeventeen SCA1 patients and 15 controls walked 30 seconds wearing 3 sensors at 3 walking speeds (preferred, slow, fast) at baseline and 1-year follow-up. Relationship between gait and clinical measures was analyzed, and standardized response means (SRMs) were calculated.
resultsToe-off angle (TOA), variability in TOA, speed, and stride length showed significant responsiveness (SRM = -1.15, 0.61, -0.77, and -0.85). TOA, which correlated most strongly with ataxia severity and patient-reported outcomes, demonstrated higher sensitivity to change than Scale for Assessment and Rating of Ataxia (SARA) in early-stage disease at preferred walking speed. Gait variability measures lacked sensitivity, possibly due to the short recording period.
conclusionsDigital gait biomarkers are promising outcomes in future clinical trials in SCA1, but their sensitivity to change appears stage dependent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.